CRNX (Crinetics Pharmaceuticals, Inc.) Earnings per share for the last four quarters

Crinetics Pharma (CRNX) - corporate logo

Crinetics Pharmaceuticals (CRNX) bases its production on outsourcing via CMO partners while utilizing its own R&D centers. The percentage change dynamics of the trailing twelve-month EPS confirm the effectiveness of this model, where -23.10 represents the latest level. The transition to oral treatment forms for rare pathologies strengthens its market position, while the humanitarian status of the sector minimizes the impact of global political conflicts.

CRNX crinetics.com Net earnings per share (EPS TTM) (02/11/2024 - 09/12/2026)

CRNX (Crinetics Pharmaceuticals): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:CRNX (Crinetics Pharmaceuticals, Inc.)
Core merchandise of Crinetics Corp

This indicator measures the year-over-year dynamics of net earnings per share, allowing for an assessment of the business's profitability scaling rates relative to its market value. By analyzing the annual growth of earnings per share over 12 months, an investor can see the impact of laboratory robotization costs and the implementation of AI predictive modeling modules on the final profitability of Crinetics Pharmaceuticals (CRNX).

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS